Orthofix Medical Inc. (NASDAQ:OFIX – Get Free Report) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $17.25.
OFIX has been the topic of a number of analyst reports. Stifel Nicolaus decreased their target price on Orthofix Medical from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. TD Cowen assumed coverage on shares of Orthofix Medical in a research report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price objective for the company. Wall Street Zen raised shares of Orthofix Medical from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Tuesday. Finally, Barrington Research reissued an “outperform” rating and set a $17.00 target price on shares of Orthofix Medical in a research note on Friday, April 10th.
Get Our Latest Stock Analysis on OFIX
Insider Buying and Selling at Orthofix Medical
Hedge Funds Weigh In On Orthofix Medical
Institutional investors have recently bought and sold shares of the company. CWM LLC increased its stake in Orthofix Medical by 99.0% during the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock worth $28,000 after acquiring an additional 955 shares during the last quarter. Gabelli Funds LLC grew its holdings in shares of Orthofix Medical by 0.4% during the 4th quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company’s stock worth $3,567,000 after purchasing an additional 1,000 shares during the period. Raymond James Financial Inc. grew its holdings in shares of Orthofix Medical by 1.5% during the 3rd quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock worth $978,000 after purchasing an additional 1,000 shares during the period. Amundi increased its position in shares of Orthofix Medical by 2.7% during the 4th quarter. Amundi now owns 41,527 shares of the medical device company’s stock worth $630,000 after purchasing an additional 1,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Orthofix Medical by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after purchasing an additional 1,213 shares during the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.
Orthofix Medical Price Performance
NASDAQ OFIX opened at $12.15 on Friday. Orthofix Medical has a 1 year low of $10.24 and a 1 year high of $16.99. The company has a market cap of $487.70 million, a price-to-earnings ratio of -5.19 and a beta of 0.82. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.45 and a quick ratio of 1.43. The stock’s fifty day moving average price is $12.43 and its 200 day moving average price is $14.03.
Orthofix Medical (NASDAQ:OFIX – Get Free Report) last announced its quarterly earnings results on Saturday, February 14th. The medical device company reported ($0.06) earnings per share for the quarter. Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%.The company had revenue of $219.91 million for the quarter. As a group, equities research analysts forecast that Orthofix Medical will post -1.57 earnings per share for the current year.
Orthofix Medical Company Profile
Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.
Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.
Further Reading
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
